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provided it is propeObjective: Describe modifications to the latest version of the Joint United Nations
Programme on AIDS (UNAIDS) Estimation and Projection Package component of
Spectrum (EPP 2013) to improve prevalence fitting and incidence trend estimation
in national epidemics and global estimates of HIV burden.
Methods: Key changes made under the guidance of the UNAIDS Reference Group on
Estimates, Modelling and Projections include: availability of a range of incidence
calculation models and guidance for selecting a model; a shift to reporting the Bayesian
median instead of the maximum likelihood estimate; procedures for comparison and
validation against reported HIV and AIDS data; incorporation of national surveys as an
integral part of the fitting and calibration procedure, allowing survey trends to inform
the fit; improved antenatal clinic calibration procedures in countries without surveys;
adjustment of national antiretroviral therapy reports used in the fitting to include only
those aged 15–49 years; better estimates of mortality among people who inject drugs;
and enhancements to speed fitting.
Results: The revised models in EPP 2013 allow closer fits to observed prevalence trend
data and reflect improving understanding of HIV epidemics and associated data.
Conclusion: Spectrum and EPP continue to adapt to make better use of the existing data
sources, incorporate new sources of information in their fitting and validation pro-
cedures, and correct for quantifiable biases in inputs as they are identified and under-
stood. These adaptations provide countries with better calibrated estimates of incidence
and prevalence, which increase epidemic understanding and provide a solid base for
program and policy planning.  2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28 (Suppl 4):S415–S425Keywords: antiretroviral therapy, mathematical models, models/projections,
people who inject drugs, surveillanceIntroduction
Since the mid-1990s, Joint United National Programme
on AIDS (UNAIDS) and country partners have
periodically produced global estimates of HIV burden
for use in both national and global planning processes [1].
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S416 AIDS 2014, Vol 28 (Suppl 4)the curve-fitting component of the Spectrum suite of
tools used for preparing national HIV estimates and
collating them globally (the software and documentation
are available from http://futuresinstitute.org/spectrum.
aspx and http://www.unaids.org/en/dataanalysis/data
tools/spectrumepp2013/). EPP regularly implements
changes and updates to improve its own methods and
technologies as recommended by the Reference Group at
its periodic meetings.
The study describes the content of and justification for
the key improvements made to EPP 2013 since the
previous update in 2011 [3,4]. These improvements
include: better choices of the outputs used to represent
national prevalence and incidence trends; an expanded
selection of models with new calibration procedures;
adjustments to the antiretroviral therapy (ART) inputs
for ART in those aged 50 years and above; and newly
improved estimates of mortality among people who
inject drugs (PWID). This study describes the most
important changes to provide a better understanding of
the tools and techniques being used to project national
and global HIV epidemics. The study concludes with a
review of ongoing issues under discussion by the
Reference Group for possible inclusion in EPP 2015
and subsequent versions.Methods
Expanded range of models in EPP 2013
The underlying mathematical models for prevalence
trends included in EPP have evolved substantially as needs
have changed. In 2001, an epidemiologically motivated
model was introduced, now referred to as EPP Classic. It
remains available in EPP 2013 and is documented in
depth in earlier studies [2,5]. EPP Classic is used when the
HIV epidemic rises and then settles into a stable
prevalence plateau of the type commonly seen in sub-
Saharan African or key population epidemics. EPP
Classic has a fixed force of infection, r, which is the rate at
which susceptible individuals acquire disease. In the real
world, this force of infection is determined by the levels,
frequency and transmission probabilities of different
risk behaviors.
The simple model with a fixed force of infection,
however, lacked the flexibility to fit countries such as
Uganda, where antenatal clinic (ANC) prevalence fell
rapidly as risk behaviors declined in the 1990s [6,7], and
then began to rise again between 2005 and 2011 as
condom use declined and ART scaled up [8]. Recogniz-
ing that risk behaviors might rise and fall over time, which
will increase and decrease the force of infection, the
variable-r model was introduced in EPP 2011 [3]. In this
model, the force of infection r was allowed to vary at each
time step, which would allow declines in prevalencefollowed by resurgences. However, despite attempts to
constrain the rates of change, the variable r often
produced incidence curves that were quite jagged, rising
and falling rapidly over the space of a few years. Many
national estimation teams were dissatisfied with the
resulting trends, so the attention turned to models that
would still allow the force of infection to vary, but which
would ensure slower and more believable changes in
incidence over time. Two suchmodels were added to EPP
2013: r-spline and r-trend.
The r-spline model allows the force of infection
parameter r to vary over time by modeling rðtÞ as a
function of time with splines [9,10]. Smooth curves for
rðtÞ are generated using a Bayesian analog to B-splines in
which changes in the slope of rðtÞare penalized with a
second-degree difference penalty, formulated as prior
distributions around changes in adjacent spline coeffi-
cients (bi), expressed as [9,11]:
bi ¼ bi1 þ ðbi1  bi2 þ uiÞ
By allowing
uiNormalð0; t2Þ
the amount of smoothness is determined by the variance
parameter t2, which is also estimated, assuming a prior
distribution t2 InverseGammað0:001; 0:001Þ [9,11].
The spline basis is comprised of seven evenly spaced
basis functions, which results in nine unknown para-
meters to estimate, namely seven spline coefficients, t2,
and the initial pulse of infection to seed the epidemic [9].
The model is fit via incremental mixture importance
sampling [12].
Short-term projections beyond the past year with
surveillance data are important outputs from EPP. To
facilitate these projections, the r-spline model incorpor-
ates a prior distribution for values of rðtÞ beyond the past
year of data that directs the model towards an equilibrium
value for prevalence and helps stabilize spline-based
trends in rðtÞ near the data boundary [9]. In a limited
number of cases, using the equilibrium prior can lead to
rapidly changing, implausible patterns of incidence when
projecting beyond the data. To address this, a random-
walk approach to projecting with r-spline as described in
[10] is implemented. This involves first fitting the spline-
based model, including the equilibrium prior for r, to the
full projection period (e.g. to 2020), after which the
posterior draws for rðtÞ are truncated at the last year of
data, and then for each draw, re-projected beyond the last
year of data by modeling changes in r with a randomwalk.
Thus, future projections assume a constant force of
infection in expectation. For the random walk, future
changes in logrðtÞ are modeled by drawing from normal
distributions to determine new values for rðtÞ at each
time step [i.e. logrðtÞNormalðlogrðtÞ; s2Þ], using an
Improvements in EPP 2013 Brown et al. S417empirical variance term (s2) calculated as the mean of the
squared differences in adjacent values for rðtÞ during the
in-sample projection period. The variance of the random
walk increases proportionally with time since the last year
with observed data, modeled as s2t ¼ s2t1ðt  t1Þ, where
t1 is the last year with observed data, so that variability
increases with the duration of the prediction. This
approach to projection was validated with out-of-sample
posterior predictive checks, and compared favorably to
the variable-r model in EPP 2011 [10].
The r-trend model [13] offers a compromise between the
variable-r model and the EPP Classic model by
summarizing the most likely trends of infection rates in
a parsimonious way. For instance, the force of infection
starts at a high level to initiate the epidemic, gradually
declines as the epidemic spreads out in the general
population, and changes less dramatically in the late
period, for example, after 2000, compared to the starting
period. To acknowledge these commonly observed
phenomena, the r-trend model assumes a systematic
change of the force of infection on the log scale:
logðrtþ1Þ  logðrtÞ ¼ b1ðb0  rtÞ þ b2rt þ b3gt
where rt is HIV prevalence and g t is the relative change of
prevalence in the late period of the epidemic. In addition
to bs, the input parameters include the starting time of
epidemic, the initial value of the force of infection, and
the bias between ANC data and national population based
survey data. Informative prior distributions for those
parameters have been derived by summarizing results
from 62 datasets, so that information on the dynamics of0
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Fig. 1. Prevalence fits and incidence trends produced by the varia
from (a) Kenya urban and (b) Rwanda.Note how the latter two mod
the projection.HIV/AIDS epidemics is pulled together across multiple
countries.
Figure 1 shows a comparison of the fits to prevalence and
incidence resulting from the three models with varying
rðtÞ described above. The r-trend and r-spline models
produce smoother incidence curves than the variable-r
model, which better agrees with the expectation that the
force of infection will evolve smoothly over time. Given
the variety of models available in EPP 2013, UNAIDS ran
a careful comparison of the different models on a large
variety of country data sets. The two newer ‘smooth-r’
models generally outperformed the variable-r and EPP
Classic models, providing closer fits to the data on a
number of metrics. This led UNAIDS to develop a set of
guidance summarized in the flow chart shown in Fig. 2.
It is worth noting, however, that experience with these
models in large numbers of countries has shown that the
guidance provided should not be strictly followed if there
is reason to believe that the character, quality and
coverage of surveillance sites have been changing over
time. In some cases, the more rigid ‘epidemiological’
structure imposed by EPP Classic may be preferable to
allowing those models that vary r over time to follow too
closely data with its own problems.
Shifting to the Bayesian median as a better
measure of ‘best fit’
Versions of EPP prior to 2013 created the national best fit
curve as a sum of the maximum likelihood estimates for
each subpopulation. The maximum likelihood estimate19
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ble-r, r-trend and r-spline models on the same urban data set
els produce smoother incidence trends over the time frame of
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Are there at least 3 
data points among the key
populations in your country
For each sub- population:
Are there more than 3 data
points from 3 consistent sites?
For each sub-population:
Are there more than 50 sites over
more than 10 years or is the epidemic
trend complex
Workbook R spline or
EPP classic 
Use R- Spline Use R- Trend
Only use as a very last resort Default model is R spline
If not enough data are 
available to create a curve 
structure or a trend: Use
EPP Classic 
The default model For Countries with very large
amounts of data or complex
trends
Concentrated epidemic Generalized epidemic
No Yes
No Yes
No Yes
EPP Classic
Consider using
sub- regional 
projection
What type of epidemic exists in 
your country?
Fig. 2. Flow chart for choice of model to use for fitting. The algorithm above is recommended for deciding which of the three
models (r-spline, r-trend or EPP Classic) should be used depending on the type of epidemic, number of sites and number of data
points.was defined as that model-generated curve which
maximizes the likelihood of the data given the model.
In reviewing the results of the 2009 and 2011 rounds of
projections in sparse data settings, two key issues were
noted that were substantially altering the national
projections in a few countries. The first issue was that
where data for a key population are very sparse, which is a
common occurrence in concentrated epidemic settings,
the maximum likelihood estimate could vary substantially
with the addition of just a single data point. The top set of
graphs in Fig. 3 shows an example of the variation that
sometimes occurred in sparse data situations with the
addition of a single point. Such changes in one or more of
the maximum likelihood estimates chosen for key
subpopulations could substantially alter national fits in
regions such as Latin America where data were often
limited.
Using a single curve to represent the fit failed to capture
the diversity of possible epidemic curves that were
consistent with the data. In Fig. 3, each of the gray curves
shown is a possible fit to the data. The dashed blue lines
represent the 5th and 95th percentiles of point estimatestaken from the 3000 resampled curves in any given year.
To better represent the mix of possible curves, EPP 2013
now reports the year-by-year median of those curves
resampled during the Bayesian fitting procedure as the
summary measure for EPP on prevalence; incidence is
estimated the same way, as a median of the resampled
incidence curves corresponding to each prevalence curve.
These are referred to as the Bayesian medians. As the
bottom set of graphs in Fig. 3 shows, this produces a much
more stable curve when minimal additional data are
added. This greatly improved the stability of fits,
especially in sparse data situations.
Better assessing the early stages of the epidemic
The second issue that often altered both fitted prevalence
curves and the resulting mortality estimates was the shape
of the curve during early years of the epidemic. Some
countries had relatively little data before the natural
history peak of the prevalence curve; in such situations the
earlier phases of the epidemic could vary greatly
depending on the model chosen. The models vary in
the way in which they initiate the epidemic. EPP Classic
and r-trend create a specified low prevalence of HIV
Improvements in EPP 2013 Brown et al. S419
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Fig. 3. Top: an example of major changes in the best fit curve in a sparse data situation when an additional data point is added.
The blue curve is the maximum likelihood estimate before and after the addition of a single additional data point. Bottom: The
same data set fit using the Bayesian median as the measure of ‘best fit’ instead of the maximum likelihood estimate. Note the
increased stability in the trend.infection (0.0025%) in a start year that varies over a
specified range of possible years, whereas r-spline allows
the prevalence level of this initial pulse of infection to
vary, but uses a fixed start year. In limited early data
situations this often led to substantial differences in the
shape of the prevalence curves during the earliest stages of
the epidemic.
In order to address this, a Data Check page was added
which allowed countries to compare the trend in early
reported AIDS cases and HIV infections with the trends
predicted by the model. With assistance from WHO, adatabase for AIDS cases was developed and is included
with the Spectrum/EPP software. For each country the
database contains the number of reported AIDS cases
between 1979 and 2001. Alternatively, countries can
enter their own reported AIDS or HIV infection data.
The EPP Data Check page then allows comparison of the
trends in the reported cases with the model predictions;
the reported cases can also be adjusted to put them on the
same scale as the model predictions. This provides
feedback on whether the epidemic is starting too early or
too late, and allows a return to the fitting page to adjust
epidemic start times and rates of growth. Figure 4 shows
S420 AIDS 2014, Vol 28 (Suppl 4)
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Fig. 4. The EPP Data Check page allows users to compare reported AIDS case and HIV infection trends with those predicted by
themodel. In cases when there is no early surveillance data, this can help countries to set a reasonable start time and early trend for
their epidemics. The projection on the top is starting too early, while the one on the bottom gives a reasonable fit through the period
when AIDS case reporting dropped off. EPP, Estimation and Projection Package component of Spectrum.
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Table 1. Values of the ANC ratios (CCr) and mean probit offsets
(CCp) used for calibration of ANC data.
Urban Rural
Data source/region CCr CCp CCr CCp
ANC-fitted data (all surveys)
Eastern Africa 1.023 0.012 0.940 0.027
Southern Africa 0.841 0.142 0.937 0.038
Western/Central Africa 0.699 0.165 0.594 0.236
All countries 0.810 0.112 0.675 0.171
These are calculated for urban and rural settings in three regions of
Africa. ANC, antenatal clinic.two examples comparing against AIDS cases. On the top,
the model predicts too early a start compared to the rate
of growth in AIDS cases, whereas the trend on the
bottom looks reasonable. Of course, interpretation of the
reported trends must be informed by an understanding of
the AIDS and HIV reporting systems in the country and
how capture rates and reporting fractions have evolved
over time.
National surveys in the fitting and calibration
procedures
In the earlier versions of EPP, fitting was first done to the
ANC data alone excluding any national survey data.
Normally, these curves would come out high relative to
the national surveys. After a set of curves was resampled in
a Bayesian framework, a subsequent step calculated an
average downward calibration for these resampled curves
across all national survey years. Once this calibration was
applied to each ANC curve, the likelihood of each down-
calibrated curve relative to the national survey data in the
country was combined with the ANC likelihood to
estimate the overall likelihood. Then a final resampling
step on the combined likelihoods was taken to get the
final sample of curves displayed in the EPP interface. This
procedure evolved incrementally as survey data became
more readily available.
In EPP 2013, the decision was made to rethink this
approach holistically. Instead of down-calibrating after
fitting, it was decided to treat the surveys as the ‘gold
standard’ to which the model should be fit. Thus, an
additional calibration parameter for the ANC data was
added to the set of model parameters, recognizing that
ANC data were generally higher than the national
prevalence estimates. The likelihood is calculated based
on the probit-transformed prevalence for ANC data,Wst,
and survey data, Wt, respectively:
ANC : Wst ¼ F1ðrtÞ þ cþ bs þ eancst
Survey : Wt ¼ F1ðrtÞ þ edhst
where F1ðrtÞ is the probit-transformed model preva-
lence at time t; c is the calibration constant for the ANC
data, expressed as a probit-offset; bs is a random effect for
site s; and eanct and e
dhs
t are error terms for the ANC and
national survey, respectively. F1 is the inverse of the
cumulative standard normal distribution. A prior
distribution for the calibration parameter, c, was specified
by a normal distribution with mean of 0.15 and an SD of
1.0, and samples from this distribution were used to
calibrate the ANC data during the likelihood calculation.
The national survey likelihoods are therefore calculated
based on uncalibrated curves and combined with the
down-calibrated ANC likelihoods during the fitting
process. The outcome then is a set of curves with different
calibration parameters for the ANC data which tries to fit
the shape of both the ANC and survey data. These
calibration parameters are then averaged to give theoverall adjustment required for the ANC data relative to
the surveys.
The advantages to this approach include: surveys, which
are considered more representative than the ANC data
and are at the core of the fitting process; in countries with
multiple surveys, the trend in the surveys themselves
inform the shape of the prevalence curve; and a wider
range of curves is considered than was the case with the
older method, which might reject curves that were good
fits to the survey data during the initial ANC data
only resampling.
Improvements to ANC calibration in countries
without surveys
There are a limited number of generalized epidemic
countries without national surveys: Angola, Eritrea,
Gambia, Namibia and Togo. In order to estimate the
ANC calibrations needed in these countries, a reviewwas
undertaken using the methodology first developed by
Gouws et al. [14] with an updated set of 48 population
prevalence surveys in 24 countries. This analysis
calculated median survey : ANC ratios (CCr) and mean
probit offsets (CCp) for application to postfitting
calibrations in urban and rural settings. The CCr is the
median of ratios of the survey prevalence to the ANC
prevalence across available countries and survey years in
the specified region, whereas the CCp is the median of
the difference between the probit-transformed preva-
lence for each survey, F1ðrdhst Þ, and that year’s probit-
transformed fitted ANC prevalence, F1ðranct Þ.
Table 1 presents these results as calculated for 3 regions in
Africa: Eastern, Southern and Western/Central. This
work is discussed in more depth in Marsh et al. elsewhere
in this volume [15]. The key findings of this study
included recognizing that substantial variation in the
calibrations was required from country to country. As
such, the single urban/rural adjustment used in past
versions of EPP may have distorted the levels of previous
curves in some countries without surveys. The results
agreed fairly well with the previous downward urban
adjustments, but found a larger downward adjustment was
needed for rural epidemics. However, as fewer and fewer
S422 AIDS 2014, Vol 28 (Suppl 4)generalized epidemic countries are without surveys, these
results should not substantially alter global estimates.
Adjusting numbers on antiretroviral therapy to
include only 15–49-year-old adults
Spectrum and EPP incorporate national data about the
number of adults on ART to account for the increased
survival for those on treatment when inferring trends in
HIV incidence from the HIV prevalence data to which
the model is calibrated. National data inputted into
Spectrum report the total number of adults over the age of
15 years who are on ART. In the past, these data were
passed directly to EPP from Spectrum. However, because
the EPP population model represents only the population
aged 15–49 years, EPP 2013 includes an adjustment of
the number of adults on ART from Spectrum to account
for the proportion who are over 50 years. Failing to adjust
the number of adults on ART to represent only the
population aged 15–49 years will result in under-
estimating HIV incidence and overestimating the decline
in incidence rate during the ART period. This is because
assuming that too large a fraction of 15–49-year-old
adults are on ARTwill result in fewer HIV deaths and thus
fewer new infections required to produce the observed
HIV prevalence.
As ART programs mature, HIV patients on treatment
survive to older ages, increasing the proportion of adults
on ARTwho are over the age of 50 years. A study of the
fraction of adult ART patients who are over 50 years from
2005 to 2010 in Rwanda, Kenya, Mozambique, and
Tanzania based on patient data from clinics supported by
International Center for AIDS Care and Treatment
Programs (Columbia University) (ICAP) found 10% of0.0000
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Fig. 5. Percentage of population on ART over age 50 for 2005 to
Spectrum based on epidemic patterns, eligibility criteria, and trenadult ART patients were over the age of 50 years with
the number increasing over time [16]. This increase is
projected to continue as ART programs mature (Fig. 5).
Future changes in ART eligibility towards earlier
initiation could increase the share of younger adults on
treatment for a time, but the long-term trend will be
towards an increasing proportion of older adults on
treatment, especially in settings of declining incidence.
Figure 5 shows several trends as projected by the age-
structured model for those on ART in Spectrum.
EPP 2013 has been revised to adjust for the percentage of
adults on ART who are 15–49 years old dynamically
accounting for the maturity of the ART program and
ART eligibility. The Spectrum model initiates HIV-
positive adults on treatment according to their eligibility
and ART need to achieve the number of adults on ARTat
the end of the year in national reporting (Stover et al., this
volume) [17]. These persons are removed according to
age and duration-specific mortality rates for people on
ART, allowing calculation of the percentage of ART
patients who are less than 50 years of age. This is passed to
EPP for incidence estimation in a Spectrum-generated
database.
Improved mortality estimates for people who
inject drugs
Compared to their nondrug-using peers, PWID experi-
ence higher rates of mortality from non-AIDS-related
causes, most commonly due to fatal drug overdose
[18]. This excess non-AIDS mortality was previously
accounted for in EPP by applying a higher per-capita
mortality rate for this key population, set as the additional
mortality attributed to being an injecting drug user added20
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2020 for various countries. These trends were generated by
ds in antiretroviral therapy (ART) uptake.
Improvements in EPP 2013 Brown et al. S423to the mortality rate of the general population [19]. The
default value for injecting drug use-specific additional
mortality was set as 1.08% per year on the basis of a 2006
review of 31 studies (all from high-income countries)
measuring mortality in cohorts of PWID [20].
A more recent systematic review and meta-analysis which
included a greater number of studies from a more diverse
range of settings [21] was updated to derive revised
estimates of non-AIDS mortality among PWID (see
Mathers et al. in this supplement for further details) [22].
The pooled crude mortality rate for non-AIDS mortality
of 2.51 [95% confidence interval (CI) 1.96, 3.05] per 100
person-years of follow-up among HIV-positive injecting
drug users derived from this analysis has now been applied
in EPP as the default additional mortality rate for PWID,
whereas a somewhat lower 1.6 per 100 person-years is
used for HIV-negative PWID.
The continued lack of data from low and middle-income
countries and the substantial heterogeneity of the cohorts
available for inclusion in this analysis prevented the
derivation of suitably robust estimates of non-AIDS
mortality specific to geographic regions, country income
level, or the availability of interventions (namely opioid
substitution therapy) that are known reduce drug use
related mortality (Mathers et al., this supplement) [22].
Other improvements to speed fitting
The variable-r model used in EPP 2011 was extremely
slow in fitting countries with large numbers of sur-
veillance sites. A number of changes and recommen-
dations have beenmade to speed this. First, the algorithms
for r-spline and r-trend are substantially faster because
they have fewer overall parameters to be fit relative to the
variable-r model. Second, EPP 2013 can take advantage
of the multiple compute cores available in new processors.
On theModel Parameters page, the number of cores to be
used can be set, which will generally produce a speed-up
comparable to the number of cores used. Finally, the
Reference Group is strongly encouraging those countries
with large numbers of sites to move from national urban/
rural models to subnational regional models, taking
advantage of the large amount of data they have to
provide more local information to guide local responses.
Together, these have resulted in much faster fitting and
improved user experiences.Results and discussion
The changes described above have led to substantial
improvements in the user experience with EPP. Fitting
with the new models is substantially faster and the
resulting curves are generally smoother than was the case
with the earlier variable-r model. The shift from a
maximum likelihood estimate to the Bayesian median ofresampled curves has provided less variability and more
stability to country models from round to round, while
simultaneously encouraging more focus on the range
of possible fits to the data in sparse data settings.
Encouraging use of early AIDS case data in setting
presurveillance trends improves the early stages of the fits,
providing more realistic start years and early epidemic
trends. Updates in the use of national surveys, improved
calibration for generalized epidemics without surveys,
and better handling of the impacts of ART in those aged
50 years and above and of mortality among PWID bring
EPP’s projections closer to reality. The revised models in
EPP 2013 allow closer fits to observed prevalence trend
data and correct for improving understanding of HIV
epidemics and associated data.
As always, EPP is, however, a work in progress. In the
very near future, a number of key issues are likely to
require further improvements and modifications. The
dynamic model in EPP reconstructs the HIV prevalence,
incidence and mortality in the past. However, only
prevalence datasets from ANCs, other surveillance
sources, and national surveys have been used to validate
the model outputs so far. Today, new information onHIV
incidence, for example, incidence assays based on
biomarkers, and HIV mortality, for example, vital
registration data in Latin America have become available.
Those datasets may be used by the EPP model to gain
more insight into the epidemics. For instance, Bao et al.
2014 (current supplement) [23] incorporate incidence
assays into the EPP framework by introducing an
additional likelihood term.
Work is also underway to explore the potential of using
r-trend to develop a hierarchical model for its input
parameters. Empirical results suggest that some model
parameters are more similar between regions (e.g. urban
and rural) within a country than between similar regions
in different countries. Therefore, r-trend can be used to
inform appropriate model development in sparser data
situations, for example, in rural areas with less surveillance
data, by assuming that the starting years of HIV/AIDS
epidemics or the biases between ANC data and survey
data are similar for urban and rural regions of the same
country.
Another substantial challenge that must be faced soon is
the shift in many countries from ANC-based surveillance
to the use of Prevention ofMother To Child Transmission
(PMTCT) datasets. There are several potential challenges
that come with these new datasets. Although ANC
datasets and PMTCT datasets are both collected from
ANCs, there may be substantial differences in test quality
and data reporting completeness between them, especi-
ally considering that such issues continue to plague
national ART data reporting, another large program-
matically generated dataset. Those factors must be taken
into consideration when transitioning from ANC data to
S424 AIDS 2014, Vol 28 (Suppl 4)PMTCT data. The PMTCT datasets may have much
larger sample sizes and cover more clinics than ANC
datasets, so that they may dominate the likelihood in EPP
models. This may require modified algorithms to adjust
for this dominance and avoid numerical underflow/
overflow problems. PMTCT sites may have different
geographical distributions than ANC sites. Using the
same set of EPP parameters to fit the combined PMTCT
and ANC datasets for the whole country might be
problematic if the epidemics are heterogeneous across
geographical regions.
One final major challenge arising is the issue of what level
of incidence reduction to use for those on ART.Whereas
the HIV Prevention Trials Network 052 study (HPTN
052) trial reported a 96% reduction in transmission [24],
ART programs in the field are not as strong or as
comprehensive as the care provided to people in the trial.
Some programs have a hard time achieving high levels of
viral suppression given problems with late initiation of
ART, poor support systems, low adherence and high loss
to follow-up. In these situations, it is unlikely that the full
levels of incidence reduction observed in clinical trials
will be achieved in real-world programs. Moreover, using
current assumptions the rapid ART scale-up in many
countries creates ‘bumps’ in the EPP-projected preva-
lence and incidence curves, which country experts find to
be unrealistic. Efforts are currently underway to see if the
level of incidence reduction should be fit as another
parameter in EPP.
These issues, which are already under active discussion by
the Reference Group, demonstrate that Spectrum and
EPP will continue to adapt to meet new challenges,
evolving surveillance methodologies, and availability of
new sources of data. In doing so, they will continue to be
valuable tools to countries in planning future needs and
improving programs to deal with an ever changing
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